# Paeds Resus Document Cross-Reference Summary

**Purpose:** Ensure consistency and completeness across all foundational documents  
**Date:** January 31, 2026  
**Documents Reviewed:**
1. System DNA V6.0 (Source document)
2. DNA V6 Audit Report
3. PR-DC V1.0 Drug Compendium
4. Clinical Guideline V1.0

---

## Cross-Reference Matrix

### DNA Axioms → Document Implementation

| DNA Axiom | PR-DC Implementation | Clinical Guideline Implementation | Status |
|-----------|---------------------|-----------------------------------|--------|
| Safety > Speed > Completeness | Max doses enforced, contraindication warnings | Sequential ABCDE prevents skipping steps | ✅ Aligned |
| ABC before diagnostics | Drugs organized by clinical context | Assessment precedes diagnosis in all protocols | ✅ Aligned |
| Clinical signs > labs | Dosing based on weight/clinical status | PAT, vital signs before labs | ✅ Aligned |
| Conservative defaults | Lower end of dose ranges as starting point | Fluid boluses with reassessment | ✅ Aligned |
| Hard blocks for lethal errors | Contraindications listed, concentration warnings | Critical decision points highlighted | ✅ Aligned |
| Mandatory reassessment | Reassessment timers for each drug | Reassessment after every intervention | ✅ Aligned |
| Offline-first | Static document, no external dependencies | Static document, no external dependencies | ⚠️ Platform needs implementation |
| Early help-seeking | Escalation triggers defined | Escalation triggers at each step | ✅ Aligned |

### Drug Coverage Cross-Reference

| DNA Drug Category | PR-DC V1.0 Coverage | Clinical Guideline Protocol | Gap Status |
|-------------------|---------------------|----------------------------|------------|
| **Cardiac Arrest & Shock** | Epinephrine (all personas), Norepinephrine, Dopamine | Cardiac Arrest Protocol, Septic Shock Protocol | ✅ Complete |
| **Arrhythmias** | Adenosine, Amiodarone | SVT Management, VF/pVT in Arrest Protocol | ✅ Complete |
| **Seizures** | Midazolam, Lorazepam, Levetiracetam | Status Epilepticus Protocol | ✅ Complete |
| **Respiratory** | Salbutamol, Magnesium Sulfate | Status Asthmaticus Protocol | ✅ Complete |
| **Sepsis** | Ceftriaxone | Septic Shock Protocol | ✅ Complete |
| **Metabolic** | Dextrose 10% | Hypoglycemia in D assessment, DKA Protocol | ✅ Complete |
| **Anaphylaxis** | Epinephrine IM, Hydrocortisone | Anaphylaxis Protocol | ✅ Complete |
| **Toxicology** | Naloxone, Atropine (OPP) | Referenced in reversible causes | ⚠️ Needs expansion |
| **Heart Failure** | Not in V1.0 | Cardiogenic shock differentiation | ⚠️ Needs PR-DC expansion |
| **PAH** | Not in V1.0 | Not covered | ⚠️ Needs both documents |
| **Hypertensive Emergency** | Not in V1.0 | Not covered | ⚠️ Needs both documents |
| **Hematologic** | Not in V1.0 | Mentioned in hypovolemic shock | ⚠️ Needs PR-DC expansion |

### Vital Signs Consistency Check

| Parameter | PR-DC Reference | Clinical Guideline Reference | Consistent? |
|-----------|-----------------|------------------------------|-------------|
| Heart Rate by Age | Section 10.1 | Section 2.3 | ✅ Yes |
| Respiratory Rate by Age | Section 10.2 | Section 2.2 | ✅ Yes |
| Blood Pressure by Age | Section 10.3 | Section 2.3 | ✅ Yes |
| Hypotension Formula | SBP < 70 + (age × 2) | SBP < 70 + (age × 2) | ✅ Yes |

### Equipment Sizing Consistency

| Equipment | PR-DC Reference | Clinical Guideline Reference | Consistent? |
|-----------|-----------------|------------------------------|-------------|
| ETT Size | Section 9.1 | Referenced in Airway | ✅ Yes |
| Defibrillation Energy | Section 9.2 | Cardiac Arrest Protocol | ✅ Yes |
| LMA Size | Section 9.1 | Referenced in Airway | ✅ Yes |

### Drug Dosing Consistency Check

| Drug | PR-DC Dose | Clinical Guideline Dose | Consistent? |
|------|------------|-------------------------|-------------|
| Epinephrine (Cardiac Arrest) | 0.01 mg/kg IV/IO | 0.01 mg/kg q3-5 min | ✅ Yes |
| Epinephrine (Anaphylaxis) | 0.01 mg/kg IM | 0.01 mg/kg IM | ✅ Yes |
| Adenosine 1st dose | 0.1 mg/kg (max 6 mg) | 0.1 mg/kg (max 6 mg) | ✅ Yes |
| Adenosine 2nd dose | 0.2 mg/kg (max 12 mg) | 0.2 mg/kg (max 12 mg) | ✅ Yes |
| Midazolam (Seizure) | 0.2 mg/kg IM/IN | 0.2 mg/kg IM/IN | ✅ Yes |
| Lorazepam (Seizure) | 0.1 mg/kg IV | 0.1 mg/kg IV | ✅ Yes |
| Levetiracetam | 40-60 mg/kg | 40-60 mg/kg | ✅ Yes |
| Salbutamol | 2.5-5 mg nebulized | 5 mg nebulized | ✅ Yes |
| Magnesium Sulfate (Asthma) | 25-50 mg/kg | 40 mg/kg | ✅ Yes |
| Ceftriaxone | 50-100 mg/kg | 80 mg/kg | ✅ Yes |
| Dextrose 10% | 2-5 mL/kg | 2-5 mL/kg | ✅ Yes |
| Amiodarone | 5 mg/kg | 5 mg/kg | ✅ Yes |
| Defibrillation | 2 J/kg, then 4 J/kg | 2 J/kg, then 4 J/kg | ✅ Yes |
| Fluid Bolus (Sepsis) | 20 mL/kg | 20 mL/kg | ✅ Yes |

---

## Identified Gaps Requiring Future Work

### Priority 1: Critical for Mission (Address in V1.1)

| Gap | Impact | Recommended Action |
|-----|--------|-------------------|
| Offline architecture not specified | System fails when needed most | Define service worker + IndexedDB schema |
| Neonatal protocols missing | Neonates excluded from care | Create neonatal module |
| Trauma protocols missing | Leading cause of pediatric death | Create trauma module |
| Heart failure drugs missing from PR-DC | Cardiogenic shock undertreated | Add furosemide, digoxin to PR-DC |

### Priority 2: Important for Completeness (Address in V1.2)

| Gap | Impact | Recommended Action |
|-----|--------|-------------------|
| Hypertensive emergency not covered | Rare but lethal condition missed | Add labetalol, nicardipine protocols |
| PAH drugs not covered | Specialized population excluded | Add sildenafil, bosentan protocols |
| Toxicology protocols incomplete | Poisoning undertreated | Expand OPP, TCA, hydrocarbon protocols |
| Multi-language support undefined | LMIC adoption limited | Define translation framework |

### Priority 3: Enhancement (Address in V2.0)

| Gap | Impact | Recommended Action |
|-----|--------|-------------------|
| Provider competency framework | Inappropriate interventions | Define role-based guidance |
| Quality metrics dashboard | Cannot measure improvement | Build analytics integration |
| EMR integration | Data silos | Define HL7 FHIR compatibility |

---

## Consistency Verification Summary

| Category | Items Checked | Consistent | Inconsistent | Accuracy |
|----------|---------------|------------|--------------|----------|
| Drug Doses | 14 | 14 | 0 | 100% |
| Vital Signs | 4 | 4 | 0 | 100% |
| Equipment Sizing | 3 | 3 | 0 | 100% |
| Protocol Steps | 6 | 6 | 0 | 100% |
| DNA Axiom Alignment | 8 | 7 | 1 | 87.5% |

**Overall Consistency Score: 97.1%**

The single inconsistency (offline-first) is an implementation gap in the platform, not a document inconsistency. The documents themselves are internally consistent and aligned with the DNA.

---

## Recommendations for Platform Implementation

Based on this cross-reference, the platform should:

1. **Implement all PR-DC drug objects** as structured data that can be queried by the GPS-like clinical flow
2. **Link Clinical Guideline protocols** to specific PR-DC drug personas (e.g., Anaphylaxis Protocol → PR-DC-EPI-ANA-v1.0)
3. **Build offline capability** using the static content from these documents
4. **Create automated consistency checks** to ensure future updates maintain alignment
5. **Version control all documents** together to prevent drift

---

## Document Versioning

| Document | Current Version | Next Planned Version | Timeline |
|----------|-----------------|---------------------|----------|
| System DNA | V6.0 | V6.1 (address audit gaps) | Q1 2026 |
| PR-DC Drug Compendium | V1.0 | V1.1 (add heart failure, heme) | Q1 2026 |
| Clinical Guideline | V1.0 | V1.1 (add neonatal, trauma) | Q1 2026 |

---

*This cross-reference ensures that all foundational documents work together as a coherent system. Any future updates to one document must be reflected in the others to maintain consistency.*
